Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 80.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,345 shares of the company's stock after selling 5,662 shares during the period. Nisa Investment Advisors LLC's holdings in Neurocrine Biosciences were worth $155,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. RFP Financial Group LLC boosted its stake in Neurocrine Biosciences by 346.5% during the first quarter. RFP Financial Group LLC now owns 192 shares of the company's stock worth $26,000 after buying an additional 149 shares during the period. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Neurocrine Biosciences during the second quarter valued at $28,000. Innealta Capital LLC purchased a new stake in shares of Neurocrine Biosciences during the second quarter valued at $30,000. New Covenant Trust Company N.A. purchased a new stake in shares of Neurocrine Biosciences during the first quarter valued at $32,000. Finally, EdgeRock Capital LLC purchased a new stake in shares of Neurocrine Biosciences during the second quarter valued at $35,000. Institutional investors own 92.59% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Needham & Company LLC reissued a "hold" rating on shares of Neurocrine Biosciences in a research note on Tuesday, October 29th. Piper Sandler raised shares of Neurocrine Biosciences from a "neutral" rating to an "overweight" rating and upped their price objective for the stock from $131.00 to $159.00 in a research note on Thursday, August 29th. Oppenheimer upped their price objective on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an "outperform" rating in a research note on Friday, August 2nd. Guggenheim upped their price objective on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. Finally, HC Wainwright reiterated a "buy" rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a report on Friday, November 1st. Five equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $163.91.

Insiders Place Their Bets

In related news, Director Gary A. Lyons sold 11,570 shares of the firm's stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $150.43, for a total transaction of $1,740,475.10. Following the completion of the sale, the director now directly owns 119,047 shares of the company's stock, valued at approximately $17,908,240.21. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director William H. Rastetter sold 14,250 shares of Neurocrine Biosciences stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the transaction, the director now owns 37,491 shares in the company, valued at approximately $5,499,554.79. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Gary A. Lyons sold 11,570 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $150.43, for a total value of $1,740,475.10. Following the completion of the transaction, the director now owns 119,047 shares of the company's stock, valued at $17,908,240.21. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 47,063 shares of company stock valued at $7,023,330 in the last three months. 4.30% of the stock is currently owned by insiders.

Neurocrine Biosciences Stock Down 1.1 %

Shares of NBIX traded down $1.32 during midday trading on Thursday, reaching $123.98. The company had a trading volume of 755,182 shares, compared to its average volume of 865,071. Neurocrine Biosciences, Inc. has a 1-year low of $103.63 and a 1-year high of $157.98. The stock has a market cap of $12.55 billion, a PE ratio of 33.24 and a beta of 0.35. The firm has a 50 day simple moving average of $118.45 and a 200-day simple moving average of $133.21.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.